Compare FSFG & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSFG | SABS |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 187.6M |
| IPO Year | 2008 | N/A |
| Metric | FSFG | SABS |
|---|---|---|
| Price | $31.86 | $4.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $31.50 | $9.80 |
| AVG Volume (30 Days) | 11.3K | ★ 370.7K |
| Earning Date | 01-28-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 67.68 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $84,223,000.00 | $114,698.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.76 | ★ N/A |
| Revenue Growth | ★ 23.59 | N/A |
| 52 Week Low | $21.63 | $1.00 |
| 52 Week High | $34.10 | $6.60 |
| Indicator | FSFG | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 63.00 |
| Support Level | $31.81 | $3.93 |
| Resistance Level | $34.10 | $4.21 |
| Average True Range (ATR) | 0.54 | 0.28 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 37.07 | 82.17 |
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.